Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
2,000
Employees2,000
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
2,000
Employees2,000

NBIX Key Statistics

Market cap
16.60B
Market cap16.60B
Price-Earnings ratio
24.35
Price-Earnings ratio24.35
Dividend yield
Dividend yield
Average volume
1.66M
Average volume1.66M
High today
$164.76
High today$164.76
Low today
$159.68
Low today$159.68
Open price
$161.53
Open price$161.53
Volume
969.45K
Volume969.45K
52 Week high
$186.12
52 Week high$186.12
52 Week low
$122.14
52 Week low$122.14

Stock Snapshot

Neurocrine(NBIX) stock is priced at $163.41, giving the company a market capitalization of 16.6B. It carries a P/E multiple of 24.35.

As of 2026-08-07, Neurocrine(NBIX) stock has fluctuated between $159.68 and $164.76. The current price stands at $163.41, placing the stock +2.3% above today's low and -0.8% off the high.

Neurocrine(NBIX) shares are trading with a volume of 969.45K, against a daily average of 1.66M.

During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.

During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.

NBIX News

TipRanks 11h
Neurocrine initiates Phase 1 study of NBIP-‘1968

Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-‘1968, an inves...

TipRanks 4d
Neurocrine price target raised to $194 from $185 at Wedbush - TipRanks

...

Neurocrine price target raised to $194 from $185 at Wedbush - TipRanks
Simply Wall St 5d
Is Neurocrine Biosciences A Bargain After Strong Q2 Results And Higher Guidance?

Neurocrine Biosciences (NBIX) is back in focus after reporting strong second quarter 2026 results, lifting full year INGREZZA sales guidance, and outlining high...

Is Neurocrine Biosciences A Bargain After Strong Q2 Results And Higher Guidance?

Analyst ratings

87%

of 31 ratings
Buy
87.1%
Hold
12.9%
Sell
0%

More NBIX News

TipRanks 6d
Neurocrine Biosciences Earnings Call Signals Scaled Growth

Neurocrine Biosciences ((NBIX)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing too...

Simply Wall St 7d
Neurocrine Biosciences Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?

In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, with earnings per share rising ye...

Neurocrine Biosciences Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.